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Abstract
Patients treated with low-dose anthracyclines often show late onset cardiotoxicity. Recent studies suggest that this form of
cardiotoxicity is the result of a progenitor cell disease. In this study we demonstrate that Cord Blood Endothelial Progenitor
Cells (EPCs) exposed to low, sub-apoptotic doses of doxorubicin show a senescence phenotype characterized by increased
SA-b-gal activity, decreased TRF2 and chromosomal abnormalities, enlarged cell shape, and disarrangement of F-actin stress
fibers accompanied by impaired migratory ability. P16 INK4A localizes in the cytoplasm of doxorubicin-induced senescent
EPCs and not in the nucleus as is the case in EPCs rendered senescent by different stimuli. This localization together with the
presence of an arrest in G2, and not at the G1 phase boundary, which is what usually occurs in response to the cell cycle
regulatory activity of p16INK4A, suggests that doxorubicin-induced p16 INK4A does not regulate the cell cycle, even though its
increase is closely associated with senescence. The effects of doxorubicin are the result of the activation of MAPKs p38 and
JNK which act antagonistically. JNK attenuates the senescence, p16 INK4A expression and cytoskeleton remodeling that are
induced by activated p38. We also found that conditioned medium from doxorubicin-induced senescent cardiomyocytes
does not attract untreated EPCs, unlike conditioned medium from apoptotic cardiomyocytes which has a strong
chemoattractant capacity. In conclusion, this study provides a better understanding of the senescence of doxorubicin-
treated EPCs, which may be helpful in preventing and treating late onset cardiotoxicity.
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Introduction
The clinical use of doxorubicin, the most widely used
anthracycline, is limited by its cardiotoxic effects which include
cardiomyopathy and heart failure [1]. The most likely hypothesis
regarding doxorubicin cardiotoxicity is that doxorubicin induces
cardiomyocyte loss through oxidative stress and apoptotic cell
death [2]. Recent studies have shown that doxorubicin targets
mature differentiated cardiomyocytes as well as progenitor cells
including cardiac progenitor cells that are primitive, proliferating,
resident cells which regenerate myocytes and vessels in vivo, and
bone marrow derived endothelial progenitor cells (EPCs) that
are mobilized to peripheral circulation and home to sites of
myocardial injury [3–5]. Inhibition of the progenitor cell me-
diated self-repairing potential of the heart is now consi-
dered a major pathogenetic mechanism of doxorubicin-induced
cardiomyopathy.
A second emerging concept related to anthracycline cardiotox-
icity concerns the type of cell damage caused by these drugs.
Recent studies have shown that doxorubicin toxicity is dose-
dependent. At high doses it induces apoptosis, while at low doses it
causes a phenomenon known as stress-induced premature
senescence (SIPS) which is the result of changes in the expression
of many proteins that regulate cell cycle, cytoskeletal and cellular
architecture, and that impair cell function and may lead to late
death [6,7]. To our knowledge no experimental evidence has been
reported regarding doxorubicin-induced senescence in EPCs.
Thus, the aim of the present study was to assess the vulnerability
of EPCs to doxorubicin-induced senescence by examining both
structural and functional changes. To investigate the pathways of
this process, we focused on telomere dysfunction, mitogen-
activated protein kinases (MAPK) p38 and c-Jun N-terminal
kinases (JNK), and p16INK4A which have proven to play a role in
both doxorubicin-induced senescence in cardiomyocytes and in
senescence in EPCs induced by other types of stress.
Materials and Methods
All materials, unless otherwise indicated, were supplied by
Sigma-Aldrich (Poole, UK).
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Cell and culture conditions
Cord Blood (CB) EPCs were obtained from mononuclear cells
isolated from human umbilical CB samples obtained from the
Cord Blood Bank. Cells were isolated, cultured and characterized
as described by Corselli et al [8] and used from passage 2 to 5 at
less than 75% of confluence.
Approval from the Ethics Committee of our institution was not
necessary because CB cells were obtained in compliance with
Italian legislation and mothers gave informed written consent to
cord donation, cell banking and utilization for research purpose in
case of sample with cell content numerically unsuited for clinical
use.
Experimental design
Cells were pre-incubated for 1 hour with or without the JNK
inhibitor SP600125 (20 mmol/L (Calbiochem, Merck KgaA,
Darmstadt, Germany), and/or the p38 inhibitor SB203580
(3 mmol/L) (Calbiochem, Merck KgaA, Darmstadt, Germany).
They were then incubated with or without various doses of
doxorubicin for 3 hours [9] and analyzed at the time indicated for
each experiment. Since the MAPK inhibitors were dissolved in
0.1% dimethyl sulphoxide (DMSO), an equivalent amount of
vehicle was added to both the control and to the drug-treated
samples. Twenty-four hours after the end of the treatments, cells
were analyzed for proliferation [Bromodeoxyuridine, BrdU,
incorporation and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylterazo-
lium bromide (MTT) assay], apoptosis (single-stranded DNA,
ssDNA), Annexin V–fluorescein isothiocyanate (FITC)/propidium
iodide staining (AV/PI), F-actin, and immunoblotting. Forty-eight
hours after the end of the treatments cells were analyzed for
senescence, metaphases, cell cycle immunofluorescence and
immunohistochemistry.
We chose to analyze the level of senescence at this time point
because had it been analyzed earlier, the rate of senescent cells
would have been too low to allow statistical analysis, while in case
of longer culture times, untreated EPCs would have spontaneously
undergone replicative senescence.
Total cell lysates
Cells were lysed in lysis buffer [20 mM Tris HCl (pH 7.5),
150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP40,
2.5 mM Na2P2O7, and 1 mM b-glycerophosphate]. The following
inhibitors were added immediately before buffer was added to
cells: 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4,
1 mM NaF, and protease inhibitor mixture (Roche).
Subcellular fractionation
Cytoplasmic and nuclear fractions were obtained as previously
described [10].
Immunoblotting
Immunoblotting was performed using the previously described
procedure [9]. After various treatments, cells were processed to
determine the levels of TRF2 (clone 4S794.15, Imgenex, San
Diego, CA), p16INK4A (N-20), GAPDH (0411), phosphorylated
p38 (E-1) (ph-p38), p38 (H-147), phosphorylated JNK (G-7) (ph-
JNK) and JNK (FL) (Santa Cruz Biotechnology, Santa Cruz, CA).
ph-p38 and ph-JNK levels were evaluated at each time-point
indicated in the experiments. After incubation in horseradish
peroxidase secondary antibody, blots were visualized with ECL
substrate (Amersham Bioscences, NJ) and films were quantified by
densitometry with an image analyzer system (Syngene,UK). Filters
were stripped and reprobed with GAPDH in order to normalize
the amounts of TRF2 and p16, and with p38 and JNK antibodies
to normalize the amounts of ph-p38 and ph-JNK respectively.
SA-b-gal activity (Senescence-associated
-b-Galactosidase Staining)
Cells were stained for b-galactosidase activity as described by
Dimri [11].
The ability to induce SA-b-gal activity is a manifestation of
residual lysosomal activity at suboptimal pH (pH 6). It becomes
detectable in the course of senescence because of the increased
lysosomal content on senescent cells [12]. The number of SA-b-gal
positive cells was determined in 100 randomly chosen low-power
fields (x100) and expressed as a percentage of all counted cells.
Immunocytochemistry
The expression of p16INK4A protein was documented by
immunostaining using the procedure described elsewhere [13].
Cells were examined by light microscopy for image analysis.
Confocal microscopy
Cells were fixed and permeabilized with 4% paraformalde-
hyde/0.1% Triton X-100 for 10 minutes at 4uC immediately
before being processed for immunofluorescence. Non-specific
antibody binding was blocked by a 30 minute incubation period
with 5% (v/v) fetal calf serum. Cells were then treated with 2 mg/
ml rabbit anti p16INK4A (Santa Cruz biotechnology, Inc., Santa
Cruz, California, USA), followed by an Alexa Fluor488 anti-rabbit
secondary antibody (Invitrogen). Nuclei were identified by PI
staining. Images were taken using a Leica TCS SL2 confocal
microscope (Leica Wetzlar, Germany) equipped with argon/He-
Ne laser sources and an HCX PL APO CS 63.061.40 oil
objective. Excitation and emission wavelengths were 488 and
522 nm for the Alexa-labeling antibody and 543 and 605 nm for
PI staining, respectively.
BrdU assay
BrdU, the thymidine analog that is incorporated into the DNA
of dividing cells during S-phase, was used for mitotic labeling.
EPC-derived cells were grown on a chamber slide and treated with
or without various doses of doxorubicin for 3 h. After 24 hours,
cells were incubated with BrdU (10 mM) for 1 h, fixed in 70%
ethanol, incubated with an anti-BrdU FITC antibody (Becton
Dikinson, San Jose, CA) for 30 minutes and observed under a
fluorescence microscope [14].
MTT Assay
The assay, which is based on the reduction of the tetrazolium
salt MTT by active mitochondria to produce insoluble formazan
salt, measures mitochondrial metabolic activity and is often used as
indicator of cell viability. Cells were treated in 96-well plates,
MTT was added to each well under sterile conditions (final
concentration of 5 mg/ml), and the plates were incubated for 3 h
at 37uC. Formazan crystals were dissolved in dimethyl sulfoxide
(100 ml/well). The purple formazan crystals were formed from
yellow MTT by succinate dehydrogenase in viable cells.
Absorbance of the formazan product was measured at 570 with
a background correction at 690 nm using a microplate reader
[15].
Annexin V–fluorescein isothiocyanate (FITC)/propidium
iodide staining
Cells were labeled with AV/PI, and 100 randomly selected
fields were counted using a fluorescence microscope. The number
Doxorubicin-Induced Senescence in EPCs
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of stained cells was normalized to the total number of cells as
counted by phase contrast microscopy of the same field.
Detection and quantitation of apoptosis by ssDNA
antibodies
Cell mono layers grown on slides were exposed to various doses
of doxorubicin, and apoptotic cells were identified by ssDNA
immunostaining as previously described [16]. The number of
stained cells was normalized to the total number of cells as counted
by fluorescence microscope of the same field.
Flow cytometric analysis
Cells for cell cycle analysis were maintained in complete
medium (EGM-2-MV, Lonza, Walkersville, MD). Trypsinized
and floating cells were pooled, washed twice with PBS and
resuspended in 400 ml of hypotonic labeled solution, 5 mg/ml PI,
0.1% w/v Na citrate, 0.1%Triton X-100 in sterile water. Cells
were incubated on ice for 30 min until DNA content analysis.
Nuclear DNA content and cell cycle analysis were monitored by
Fluorescence Activated Cell Sorting (Becton Dickinson, San Jose,
CA) and data were analyzed using CellQuest software (Becton
Dickinson San Jose, CA).
Chromosome analysis
Twenty-four hours after treatment with doxorubicin, cells were
exposed to Colcemid (0.04 mg/ml) for 90 minutes at 37uC, and to
hypotonic treatment (0.075 mol/L KCl) for 15 minutes at room
temperature. Cells were fixed in a methanol and acetic acid (3:1 by
volume) mixture for 15 minutes and then washed three times in
the fixative. The slides were air-dried and stained with Giemsa for
analysis.
F-actin detection
EPCs growing on slides were fixed, permeabilized and labeled
simultaneously in PBS containing 50 mg/ml lysopalmitoyphospa-
tidylecholine, 3.7% formaldehyde and 5 units/ml of fluorescent
phallotoxin (A-12379 AlexaTM488 phalloidin, Molecular probes,
Inc). Cells were rapidly washed three times with PBS and were
viewed by fluorescent microscopy in order to carry out image
analysis [17].
EPC migration assay
EPC migration was assayed using a modified Boyden chamber
composed of a membrane with an 8 mm pore size.
EPC migration after treatment with doxorubicin. After
treatments with doxorubicin EPCs (104 cells per well) were seeded
onto chemotaxis filters in serum free EBM plus 0.1% bovine
serum albumin (BSA). EGM-2-MV containing VEGF (50 ng/ml)
was then added to the lower chamber.
EPC migration with conditioned medium from H9c2.
EPCs (104 cells per well) were seeded onto chemotaxis filters in
serum free EBM plus 0.1% bovine serum albumin. The following
were then added to the lower chamber: DMEM plus 0.1% BSA,
conditioned media from H9c2 cardiomyocytes, and EGM-2-MV
containing VEGF (50 ng/ml). In order to obtain conditioned
medium from senescent or apoptotic H9c2, we treated the cells for
3 hours with 0.1 or 1 mM doxorubicin, respectively, in growth
factor-free DMEM plus 0.1% BSA, then the H9c2 were grown in
fresh medium (growth factor-free DMEM plus 0.1% BSA) for
24 hours [9]. DMEM plus 0.1% BSA served as the control
medium and EGM-2-MV containing VEGF served as the
medium of activation.
After the 24-hour migration period, the lower side of the
nitrocellulose membrane was washed with PBS and fixed with 2%
paraformaldehyde. Cells were stained with Giemsa solution for
quantification. Migrating cells were counted manually in four
random microscopic fields [18].
Image analysis
Image analysis was performed by the Leica Q500 MC Image
Analysis System (Leica, Cambridge, UK). Three hundred cells
were randomly analyzed for each sample, and the optical density
of the signals was quantitated by a computer. The video image was
generated by a CCD Camera connected through a frame grabber
to a computer. Single images were digitized for image analysis at
256 grey levels. Imported data were quantitatively analyzed by
Q500MC Software-Qwin (Leica, Cambridge, UK). The single
cells were randomly selected by the operator by using the cursor
and then positive areas were automatically estimated.
Statistical analysis
Data are reported as mean 6 standard error (SE) of four
independent experiments. Statistical analysis was performed by
one-way ANOVA followed by Bonferroni post-hoc test and
Wilcoxon signed rank test when appropriate.
Results
Low and high doses of doxorubicin induce EPC
senescence and apoptosis
To investigate the effects of doxorubicin on senescence and
apoptosis, we performed a dose-effect curve. At doses of 0.05, 0.1
and 0.25 mM, doxorubicin did not increase the percentage of
ssDNA positive cells, while it did induce a dose-dependent increase
of SA-b-gal positivity accompanied by a flattened and enlarged cell
shape, thus suggesting a pro-senescent non apoptotic effect.
(Figure 1A, 1B). At doses of 0.5 and 1 mM, doxorubicin had a
pro-apoptotic effect documented by a dose-dependent increase in
ssDNA positivity and decrease in SA-b-gal positivity. AV/PI
staining showed that cells treated with doxorubicin 1 mM were
AV(+)/PI(-) thus showing the typical features of early apoptosis,
while cells treated with 0.25 mM were AV(+)/PI(+) (Fig. 1B). Even
though this double positivity might indicate late apoptosis or
necrosis, taking into account the results of ssDNA and SA-b-gal
analysis and in agreement with previous studies performed by
others [19] and by ourselves [7,16], this result suggests that sub-
apoptotic doses of doxorubicin induce early loss of membrane
permeability in this experimental model.
In further experiments we chose the doses of 0.25 mM and
1 mM doxorubicin to induce senescence or apoptosis respectively.
Doxorubicin induces the increase of p16INK4A with
perinuclear accumulation
We also evaluated the effects of doxorubicin on p16INK4A, a
cyclin-dependent kinase inhibitor thought to be a senescence-
associated marker. Western blot analysis documented that
untreated EPCs express very low levels of p16INK4A (Fig. 2A).
A dose effect curve shows that doxorubicin induces changes in
p16INK4A expression levels that parallel changes in the percent-
age of Sa-b-gal positive cells. Immunocytochemical analysis of
p16INK4A merged with SA-b-gal activity together with confocal
microscopy analysis of p16INK4A revealed that, in cells treated
with 0.25 mM doxorubicin, p16INK4A is increased in SA-b-gal
positive cells and that it has cytoplasmic, perinuclear localization
(Fig. 2B, 2C,). We also evaluated p16INK4A in a model of EPC
Doxorubicin-Induced Senescence in EPCs
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senescence not induced by doxorubicin [20]. After having
maintained EPCs in culture for four days after confluence, we
observed a significant increase in p16INK4A expression levels with
typical nuclear localization (Fig. 2B, 2C,). Western analysis of
total, cytoplasmic and nuclear protein extracts indicated that
0.25 mM doxorubicin induces p16INK4A accumulation in the
Figure 1. Dose-effect curve. (A) Bar-graph showing the percentages of SA-b-gal and ssDNA positive cells after treatment with various doses of
doxorubicin. (B) Photographs illustrating the effects of doxorubicin 0.25 and 1 mM. Cells were evaluated for (from top to bottom): SA-b-gal activity
(magnification,6200), ss-DNA positivity (magnification,6200), and AV/PI staining (magnification,6400). ct, control; Dox, doxorubicin. *p,0.05 vs
control.
doi:10.1371/journal.pone.0015583.g001
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Figure 2. Prosenescent doses of doxorubicin increase p16INK4A protein levels with cytoplasmic accumulation. (A) Western blot analysis
of p16INK4A expression in EPCs treated with various doses of doxorubicin. (B) Photographs show from left to right: control cells, cells cultured for four
days after confluence (overconfluence), cells treated with 0.25 mM doxorubicin; first row: merge of SA-b-gal staining (blue) and immunocytochemistry
for p16INK4A (brown) (magnification,6400)); second row, p16INK4A immunofluorescence (magnification,61000); third row, nuclear staining with PI
Doxorubicin-Induced Senescence in EPCs
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cytosol while overconfluence induces p16 accumulation in the
nucleus (Fig. 2D).
P38, JNK and oxidative stress regulate induction of
senescence and p16 INK4A
As demonstrated by previous studies, doxorubicin acts through
the activation of MAPKs and the induction of oxidative stress. We
demonstrated that the p38 and JNK pathways are activated by
0.25 mM doxorubicin, as evidenced by phosphorylation of p38
and JNK. We found no changes in total MAPK protein levels
(Fig. 3A). We then analyzed the role played by MAPKs in
mediating the effect of doxorubicin on senescence and p16INK4A
induction. Pre-treatment of EPCs with SB203580, a p38 specific
inhibitor, or SP600125, a JNK specific inhibitor, attenuated the
doxorubicin-induced increase of SA-b-gal positivity (263% and
271% respectively) and of p16INK4A protein levels (266% and
277% respectively) (Fig 3B, 3C). Pre-treatment with both
inhibitors, i.e., SB203580 and SP600125, reduced the increase
of SA-b-gal positivity by 45% and the increase of p16 INK4A
expression levels by 44%, thus resulting less effective than pre-
treatment with the individual inhibitors alone (Fig. 3B, 3C). As
shown in Figure 3D, pre-treatment with these inhibitors did not
influence the p16 INK4A localization which remained cytoplasmatic
and perinuclear. Pre-treatment with PD98059, an ERK 1/2
specific inhibitor, did not modify the effects induced by
doxorubicin (data not shown). Pre-treatment for 90 minutes with
the antioxidant NAC (10 mM) reduced the doxorubicin induced
increase of SA-b-gal positivity by 49% and of p16INK4A
expression by 56% (Fig. 3B, 3C, 3D).
We then analyzed the effects of JNK and p38 inhibitors on
ssDNA positivity. Pre-treatment with SP600125 of cells exposed to
the sub-apoptotic dose of 0.25 mM doxorubicin significantly
increased the percentage of ssDNA positive cells (20% vs 5%),
while pre-treatment with SB203580 did not produce any effects
(Fig. 3B). These results collectively show that while pre-treatment
with the specific p38 inhibitor mitigates the toxic effects of
doxorubicin, pre-treatment with the specific JNK inhibitor
decreases senescence but induces apoptosis.
F-actin disorganization induced by Doxorubicin is p38
and JNK mediated
F-actin is well organized in linear stress fibers in normal EPCs.
After treatment with Doxorubicin 0.25 mM, cells appeared
enlarged, without detectable changes in the total amount of F-
actin stress fibers, which, however, resulted disorganized, partially
destroyed, and thickened at the cell periphery (Fig. 4A, 4B). Pre-
treatment with p38 or JNK inhibitors reduced hypertrophy, but
while SB203580, the p38 inhibitor almost completely restored the
normal structure of the cytoskeleton, SP600125, the JNK
inhibitor, led to the disappearance of F-actin fibers. This confirms
that JNK inhibition switches cell response to doxorubicin 0.25 mM
(Fig. 4A, 4B) from senescence to apoptosis [21].
Effect of doxorubicin on EPC migration
Doxorubicin-induced cytoskeleton remodelling suggests that
doxorubicin may alter the migratory ability of EPCs. The
modified Boyden chamber assay demonstrated that the migratory
capacity of EPCs was lost in doxorubicin-treated cells (Fig. 5).
Effect of apoptotic and senescent cardiomyocytes on
EPC migration
The capacity of damaged tissue to recruit EPCs is a key event in
the process of tissue repair. We therefore investigated the effect of
conditioned medium from doxorubicin-induced apoptotic or
senescent H9c2 cardiomyocytes on EPC migration. Conditioned
medium from apoptotic cardiomyocytes stimulated EPC migra-
tion, while conditioned medium from senescent cardiomyocytes
did not produce any effect (Fig. 5).
Prosenescent doses of doxorubicin decrease TRF2 levels
and induce anomalous mitoses and cell cycle alterations
Recently we demonstrated that low doses of doxorubicin induce
senescence in cardiomyocytes by altering the TRF2 levels, thus
leading to telomere uncapping and chromosome instability [7].
Pro-senescent doses of doxorubicin also induced these effects in
EPCs. Western blot analysis showed a decrease in the protein
levels of TRF2 (Fig. 6A), and karyotype analysis revealed
chromosomal instability and breakage with structural abnormal-
ities including end-to-end fusions, string, ring and triradial
configurations. We observed increases in numerical alterations:
15% of metaphases in the treated cells had tetraploidy (92, XX)
versus 8% in untreated cells (Fig. 6B). As shown by FACS analysis
of PI–labelled cells, 0.25 mM doxorubicin did not increase the sub-
G0 phase that is typical of apoptosis, but it decreased the number
of S-phase cells by 66%, caused arrest in G2/M and confirmed the
2-fold increase in hyperploid cells (.4N phase) (Fig. 7A).
In agreement with FACS analysis, mitotic labeling through
BrdU, that is incorporated into the DNA of dividing cells during S-
phase demonstrated that doxorubicin impairs EPC proliferation
which is affected in a dose dependent manner (Fig. 7B). Also MTT
that measures mitochondrial metabolic rate documented that
doxorubicin decreases viable cell numbers, even though our data
show that in comparison with BrdU, MTT assay will provide an
underestimation of the antiproliferative effects of doxorubicin
(Fig. 7C). This is in agreement with previous studies demonstrating
that depending on the agent to be evaluated, MTT based method
may result in an underestimation of the antiproliferative efficacy
[22].
Discussion
EPCs have a very low level of replicative senescence. Replicative
senescence depends upon the degree of telomere shortening and it
occurs when the cell division rate progressively slows following a
period of rapid proliferation, and then ultimately ceases altogether.
Our experiments document that after brief exposure to sub-
apoptotic doses of doxorubicin, EPCs undergo stress-induced
premature senescence (SIPS). Unlike replicative senescence, SIPS,
which is sometimes also referred to as rapid or accelerated
senescence, is caused by telomere dysfunction without overall
shortening because the telomere could not be shortened to the
threshold length within such a short period of time [23].
(magnification, 61000); fourth row, merge of p16INK4A immunofluorescence and nuclear staining with PI (magnification, 61000).(C) Bar-graph
showing the percentage of SA-b-gal positive cells having nuclear (SA-b-gal+/p16+N) or cytoplasmic p16INK4A localizations (SA-b-gal+/p16+C) in
control, overconfluent for four days or 0.25 mM doxorubicin treated cells. (D) Western blot analysis of p16INK4A expression in EPCs treated with
0.25 mM doxorubicin or cultured for four days after confluence. ct, control; Dox, doxorubicin; overc., overconfluence; tot, total; N, nuclear; C,
cytoplasmic.
doi:10.1371/journal.pone.0015583.g002
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Figure 3. p38 and JNK control the cell response to sub-apototic doses of doxorubicin differently. (A):effects of exposure to 0,25 mM
doxorubicin on MAPK activation by western blot using antibodies specific for phosphorilated (Ph) and total p38 and JNK (left panel). Bar graph
showing values for ph-MAPK normalizzated to the amount of total enzyme and expressed as the relative increase above control value, which was set
at 100 (right panel). (B) and (C): bar-graphs showing the effects of pre-treatment with the JNK inhibitor, SP600125, the p38 inhibitor, SB203580 and
NAC on the percentage of SA-b-gal and ssDNA positive cells (panel B) and p16INK4A protein levels (panel C). (D): merge of SA-b-gal staining (blue) and
immunocytochemistry for p16INK4A (brown) in cells exposed to doxorubicin and pre-treated with or without SP600125, SB203580, or NAC
(magnification, 6400). ct, control; Dox, 0.25 mM doxorubicin. SB, p38 inhibitor; SP, JNK inhibitor. *p,0.05 vs ct; 1 p,0.05 vs Dox.; ¤ p,0.05 vs.
SP+Dox; # p,0.05 vs. SB+Dox.
doi:10.1371/journal.pone.0015583.g003
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We have previously shown that in neonatal rat cardiomyocytes
and H9c2 myoblasts [7] sub-apoptotic doxorubicin down-
regulates TRF2 whose main role is to maintain the t-loop
telomeric structure that governs chromosomal stability. In this
study we obtained similar results in EPCs, in which doxorubicin
induces TRF2 down-regulation and, as shown by metaphase
analysis, chromosomal instability, covalent fusion and mitotic
defects with consequential chromosome segregation errors. Upon
the next division, misligation of two non-matching ends results in a
chromosome with a double strand break at one end that will be
fused to another uncapped end, perpetuating a cycle of breakage-
fusion-bridge that may lead to late cell death [24,25].
Figure 4. Phalloidin staining of F-actin. (A) Photographs depict EPCs pre-treated with or without MAPK inhibitors, and then treated with 0.25 mM
doxorubicin (magnification 1000X). (B) Bar-graph showing cell size in various treatment groups. ct, control; Dox, 0.25 mM doxorubicin. SB, p38
inhibitor; SP, JNK inhibitor. *p,0.05 vs ct; 1 p,0.05 vs Dox.
doi:10.1371/journal.pone.0015583.g004
Figure 5. EPC migration assay. Graph represents the percentage of migrating EPCs assessed by a modified Boyden chamber assay; EPCs were
untreated or incubated with 0.25 mM doxorubicin and then exposed to: VEGF, medium, or conditioned medium from normal or doxorubin-induced
senescent or apoptotic H9c2 cells. ct, control; Dox, doxorubicin; SP, JNK inhibitor; SB, p38 inhibitor; ct, control; *p,0.05 vs medium; # p,0.05 vs
untreated cells exposed to VEGF; ¤ p,0.05 vs. all conditions.
doi:10.1371/journal.pone.0015583.g005
Doxorubicin-Induced Senescence in EPCs
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Previous studies have shown that SIPS is often mediated by
p16INK4A, the tumor suppression protein which is considered a
marker of cellular senescence in a number of stem cell types
including neural, hematopoietic, cardiac and pancreas islet
progenitor cells [26–29].
p16INK4A can bind and inhibit the cyclin dependent kinases 4
and 6 (CDK4 and CDK6), and at the same time it can disrupt the
CDK complexes that release other inhibitors, such as p27, which
can act by inhibiting CDK2. As a result, p16INK4A increases the
expression of the hyperphosphorylated Rb thus blocking the entry
of proliferating cells into S phase and inducing a G1 phase arrest
that contributes to cellular senescence [30].
We found that doxorubicin 0.25 mM increases the p16INK4A
protein levels which are closely associated with the amount of
senescent cells, but in agreement with previous studies we did not
find that it induced G1 phase arrest, but rather, that it produced cell
cycle arrest at G2/M boundary [3,31]. This result suggests that the
doxorubicin-induced increase of p16INK4A does not regulate the cell
cycle in this model of SIPS, even though its induction may be
associated with other aspects of the senescent phenotype. In this
respect, it is noteworthy that p16INK4A accumulates in the
cytoplasmic perinuclear zone of doxorubicin-induced senescent
cells, but not in cells that become senescent as a result of prolonged
confluence in culture. It is likely that the pathways that regulate the
senescence process may vary according to the type of stress [29,32].
Recent findings have demonstrated that p16INK4A is also involved
in the control of most events besides cell cycle regulation. Cytoplasmic
accumulation may indicate other functional aspects related to specific
phenotypes. In lung carcinoma cells it may represent a mechanism of
p16INK4A inactivation similar to what is observed in other tumor
suppressor genes [33], while in advanced gastric cancer it appears to
be a good prognostic indicator and its co-localization with anion
exchanger 1 predicts a lack of metastasis [34]. Alhaja demonstrated
that cyoplasmic p16INK4A inhibits the spreading and migration in
human umbilical vein endothelial cells, and co-localizes with a´Vb3
integrin [35]. Our experiments show that besides p16INK4A
cytoplasmic localization, the doxorubicin-induced senescent-like
phenotype is characterized by a morphologically flattened and
enlarged cell shape, an increase in SA-b-gal activity and the structural
alteration and redistribution of F-actin. This cytoskeleton remodeling
is associated with remarkable impairment of EPC migration.
The MAPK signalling that converges on JNK and p38 plays an
important role in doxorubicin-induced senescence and apoptosis
in many cell types [7,36]. A number of studies have also
established the involvement of MAPKs in stem cell senescence.
Ito and colleagues [37] demonstrated that p38 regulates
senescence and p16INK4A in hematopoietic stem cells, Zhang
[38] showed that inhibiting the p38 pathway mitigates both
senescence and the increase in p16INK4A expression induced by
TNF-a´ in human umbilical cord blood EPCs.
Figure 6. Pulsed incubation of doxorubicin induces telomeric dysfunction and G2 cell cycle arrest. Cells were cultured for 24 h after
treatment with doxorubicin 0,25 mM and then analyzed. (A)Western blot analysis of TRF2. (B) Metaphase spreads. Chromosomal abnormalities are
indicated by arrows (magnification,61000).
doi:10.1371/journal.pone.0015583.g006
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We observed that pre-treatment with a specific inhibitor of p38
reduces the number of SA-b-gal positive cells, decreases the
accumulation of p16INK4A and almost completely prevents the
structural changes of the F-actin fibers induced by doxorubicin.
On the contrary, pre-treatment with the specific inhibitor of JNK
decreases senescence but induces apoptosis, as evidenced by the
increase in ssDNA positivity and destruction of F-actin stress
fibers.
The balance between JNK and p38 activity in defining cell fate
in response to stress has already been demonstrated by other
groups [39] and by ourselves [16].
Present data confirm that p38 and JNK pathways antagonis-
tically control cellular senescence, p16INK4A expression and
structure of F-actin stress fibers in EPCs treated with doxorubicin.
JNK activation promotes cell survival by countering the negative
effects that doxorubicin induces via p38 activation.
Induction of oxidative stress is one of the mechanisms through
which doxorubicin acts. Oxidative stress appears to activate the
senescence program mainly by involving the p16INK4A-pRb
pathway through the mediation of the p38 signalling cascade
[40,41]. It is possible that in EPCs, ROS accumulation, induction
of p38 and JNK signalling that regulate p16INK4A, together with
telomere dysfunction, may jointly contribute to doxorubicin
induced senescence. In fact, NAC, an antioxidant, down-regulates
SA-b-gal positivity and p16INK4A levels, and sustains the
hypothesis that NAC acts by inhibiting the signal that is likely
induced by oxidative stress. Consistent with this finding, previous
reports [9,42] have indicated that pre-treatment with antioxidants
contrasts signalling transduced by p38 and JNK doxorubicin-
treated cells.
It has been shown that when the heart is exposed to doxorubicin
several mechanisms are activated in an attempt to promote cell
protection and tissue repair. The neuregulin/erbB2 system is
probably the most important survival pathway to be activated in
response to doxorubicin [43]. The high cardiotoxic effects of
trastuzumab, an anti-erbB2 humanized monoclonal antibody,
which has been observed in erbB2+ breast cancer patients that
have been pre-treated or co-treated with anthracyclines, depend
on the loss of this survival pathway [16,44]. EPCs also have the
potential for heart protection or repair in the course of
anthracycline treatment. A number of studies have shown that
EPCs are able to proliferate and differentiate into mature
endothelial cells [45] and to secrete paracrine factors that prevent
apoptosis of mature endothelial cells and induce hypertrophy of
cardiac muscle cells [46,47]. There is also evidence that EPCs may
trans-differentiate into cells of the myocardial lineage [48]. This
EPC function is of great interest in the light of the recent study by
Huang [5] who found that both reduced capillary density and
Figure 7. Doxorubicin induces cell cycle alterations and impairs cell viability. (A) Cell cycle analysis: the blue area represents the control
cells, the red line indicates treated cells. Cells were cultured for 24 h after treatment with doxorubicin 0,25 mM and then analyzed. Phases of the cell
cycle are indicated: Sub G0 [M1], G0/G1 [M2], S [M3], G2/M [M4], .4N [M5]. (B) Cell proliferation evaluated by BrdU incorporation. Cells were cultured
for 24 h after treatment with various doses of doxorubicin and then analyzed. BrdU data were normalized to untreated (media alone) cells (C),
Number of viable cells evaluated by MTT assay. Cells were analyzed before treatment and 24 hours after treatment with various doses doxorubicin.
ct, control; Dox, doxorubicin. *p,0.05 vs ct. 1 p,0.05 vs 0 h; # p,0.05 vs ct 24 hr.
doi:10.1371/journal.pone.0015583.g007
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reduced vascular endothelial growth factor expression in anthra-
cycline-treated hearts limit the ability of the cardiac tissue to
respond to further stress. Hamed, furthermore, found that
doxorubicin targets EPCs thereby reducing the number of cells
and impairing their function [4].
The present study takes a step forward in understanding
doxorubicin cardiomyopathy. First, it shows that pulsed exposure
to low sub-apoptotic doses of doxorubin induces premature
senescence in EPCs, and it provides us with insight into the
mechanisms of doxorubicin-induced senescence, which is needed
to further explore strategies to protect EPCs.
Secondly, it emphasizes the importance of cardiomyocyte
senescence as a major mechanism of doxorubicin cardiomyopathy
[6]. Even though senescence may be viewed as less severe than
apoptosis, present findings suggest that as compared to apoptotic
cardiomyocytes, senescent ones produce or secrete less homing
factors that would attract EPCs to the site of injury thus impairing
the heart’s ability to limit the damage.
Acknowledgments
The authors thank Dr. Maria Bertolotto, Dr. Daniela Verzola and Dr.
Barbara Villaggio (all from the Department of Internal Medicine,
University of Genova) for their expert technical assistance and Dr. Paolo
Strada (Transfusion Center, Azienda Ospedaliera-Universitaria San
Martino, Genova) for providing cord blood units.
Author Contributions
Conceived and designed the experiments: PA PS CB. Performed the
experiments: PA CB M. Passalacqua CA GF. Analyzed the data: PA PS
GG. Contributed reagents/materials/analysis tools: FF M. Podesta`. Wrote
the paper: PS PA MC.
References
1. Shan K, Lincoff AM, Young JB, Young JB (1996) Anthracycline-induced
cardiotoxicity. Ann Intern Med 125: 47–58.
2. Spallarossa P, Garibaldi S, Altieri P, Fabbi P, Manca V, et al. (2004) Carvedilol
prevents doxorubicin-induced free radical release and apoptosis in cardiomy-
ocytes in vitro. J Mol Cell Cardiol 37: 837–846.
3. De Angelis A, Piegari E, Cappetta D, Marino L, Filippelli A, et al. (2010)
Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell
pool and is rescued by restoration of progenitor cell function. Circulation 121:
276–292.
4. Hamed S, Barshack I, Luboshits G, Wexler D, Deutsch V, et al. (2006)
Erythropoietin improves myocardial performance in doxorubicin-induced
cardiomyopathy. Eur Heart J 27: 1876–1883.
5. Huang C, Zhang X, Ramil JM, Rikka S, Kim L, Lee Y, et al. (2010) Juvenile
exposure to anthracyclines impairs cardiac progenitor cell function and
vascularization resulting in greater susceptibility to stress-induced myocardial
injury in adult mice. Circulation 121: 675–683.
6. Maejima Y, Adachi S, Ito H, Hirao K, Isobe M (2008) Induction of premature
senescence in cardiomyocytes by doxorubicin as a novel mechanism of
myocardial damage. Aging Cell 7: 125–136.
7. Spallarossa P, Altieri P, Aloi C, Garibaldi S, Barisione C, Ghigliotti G, et al.
(2009) Doxorubicin induces senescence or apoptosis in rat neonatal cardiomy-
ocytes by regulating the expression levels of the telomere binding factors 1 and 2.
Am J Physiol Heart Circ Physiol 297: H2169–H2181.
8. Corselli M, Parodi A, Mogni M, Sessarego N, Kunkl A, et al. (2008) Clinical
scale ex vivo expansion of cord blood-derived outgrowth endothelial progenitor
cells is associated with high incidence of karyotype aberrations. Exp Hematol 36:
340–349.
9. Spallarossa P, Altieri P, Garibaldi S, Ghigliotti G, Barisione C, et al. (2006)
Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in
H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69:
736–745.
10. Ottonello L, Bertolotto M, Montecucco F, Bianchi G, Dallegri F (2009) Delayed
apoptosis of human monocytes exposed to immune complexes is reversed by
oxaprozin: role of the Akt/IkappaB kinase/nuclear factor kappaB pathway.
Br J Pharmacol 157(2): 294–306.
11. Dimri GP, Lee X, Basile G, Acosta M, Scott G, et al. (1995) A biomarker that
identifies senescent human cells in culture and in aging skin in Vivo. Proc Natl
Acad Sci USA 92: 9363–9367.
12. Gerland LM, Peyrol S, Lallemand C, Branche R, Magaud JP, et al. (2003)
Association ofincreased autophagic inclusions labeled for beta-galactosidase with
fibroblastic aging. Exp Gerontol 38: 887–895.
13. Verzola D, Gandolfo MT, Salvatore F, Villaggio B, Gianiorio F, et al. (2004)
Testosterone promotes apoptotic damage in human renal tubular cells. Kidney
Int 65: 1252–1261.
14. Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, et al. (2003)
Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell
mobilization. Blood 102: 1340–1346.
15. Mossmann T (1983) Rapid colorimetric assay for cellular growth and survival:
application to proliferation and cytotoxicity assays. J Immunol Meth 65: 55–63.
16. Spallarossa P, Altieri P, Pronzato P, Aloi C, Ghigliotti G, et al. (2010) Sub-lethal
doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes
sensitized by low pro-senescent doses of epirubicin: the protective role of
dexrazoxane. J Pharmacol Exp Ther 332: 87–96.
17. Multani A S, Ozen M, Narayan S, Kumar V, Chandra J, et al. (2000) Caspase-
Dependent Apoptosis Induced by Telomere Cleavage and TRF2 Loss.
Neoplasia 2: 339–345.
18. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, et al. (2001) Number and
migratory activity of circulating endothelial progenitor cells inversely correlate
with risk factors for coronary artery disease. Circ Res 89: E1–E7.
19. Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, et al. (2005) Two distinct
modes of cell death induced by doxorubicin: apoptosis and cell death through
mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24:
4765–4777.
20. Campisi J, d’Adda di Fagagna F (2007) Cellular senescence: when bad things
happen to good cells. Nature Reviews Molecular Cell Biology 8: 729–740.
21. Brown BS, Bailey K, Savill J (1997) Actin is cleaved during constitutive
apoptosis. Biochem 323: 233–237.
22. Wang P, Henning SM, Heber D (2010) Limitations of MTT and MTS-based
assays for measurement of antiproliferative activity of green tea polyphenols.
PLoS One 5: e10202.
23. Su D, Zhu S, Han X, Feng Y, Huang H, et al. (2009) BMP4-Smad signaling
pathway mediates adriamycin-induced premature senescence in lung cancer
cells. J Biol Chem 284: 12153–12164.
24. de Lange T (2002) Protection of mammalian telomeres. Oncogene 21: 532–540.
25. London˜o-Vallejo JA (2008) Telomere instability and cancer. Biochimie 90:
73–82.
26. Torella D, Rota M, Nurzynska D, Musso E, Monsen A, et al. (2004) Cardiac
stem cell and myocyte aging, heart failure, and insulin-like growth factor-1
overexpression. Circ Res 94: 514–524.
27. Sharpless NE, DePinho RA (2007) How stem cells age and why this makes us
grow old. Nat Rev Mol Cell Biol 8: 703–713.
28. Janzen V, Forkert R, Fleming HE, Saito Y, Waring MT, et al. (2006) Stem-cell
ageing modified by thecyclin-dependent kinase inhibitor p16INK4a. Nature
443: 421–426.
29. Molofsky AV, Slutsky SG, Joseph NM, He S, Pardal R, Krishnamurthy J (2006)
Increasing p16INK4a expression decreases forebrain progenitors and neuro-
genesis during ageing. Nature 443: 448–452.
30. Yang DG, Liu L, Zheng XY (2008) Cyclin-dependent kinase inhibitor
p16(INK4a) and telomerase may co-modulate endothelial progenitor cells
senescence. Ageing Res Rev 7: 137–146.
31. Vigneron A, Roninson IB, Gamelin E, Coqueret O (2005) Src inhibits
adriamycin-induced senescence and G2 checkpoint arrest by blocking the
induction of p21waf1. Cancer Res 65: 8927–8935.
32. Herbig U, Jobling WA, Chen BP, Chen DJ, Sedivy JM (2004) Telomere
shortening triggers senescence of human cells through a pathway involving
ATM, p53, and p21(CIP1), but not p16(INK4a). Mol Cell 1: 501–513.
33. Evangelou K, Bramis J, Peros I, Zacharatos P, Dasiou-Plakida D, et al. (2004)
Electron microscopy evidence that cytoplasmic localization of the p16(INK4A)
"nuclear" cyclin-dependent kinase inhibitor (CKI) in tumor cells is specific and
not an artifact. A study in non-small cell lung carcinomas. Biotech Histochem
79: 5–10.
34. Liu Q, Song, LJ, Xu WQ, Zhao L, Zheng L, et al. (2009) Expression of
cytoplasmic p16 and anion exchanger 1 is associated with the invasion and
absence of lymph metastasis in gastric carcinoma. Molecular Medicine Reports
2: 169–174.
35. Alhaja E, Adan J, Pagan R, Mitjans F, Cascallo´ M, et al. (2004) Anti-migratory
and anti-angiogenic effect of p16: a novel localization at membrane ruffles and
lamellipodia in endothelial cells. Angiogenesis 7: 323–333.
36. Nelyudova A, Aksenov N, Pospelov V, Pospelova T (2007) By blocking
apoptosis, Bcl-2 in p38-dependent manner promotes cell cycle arrest and
accelerated senescence after DNA damage and serum withdrawal. Cell Cycle 6:
2171–2177.
37. Ito K, Hirao A, Arai F, Takubo K, Matsuoka S, et al. (2006) Reactive oxygen
species act through p38 MAPK to limit the lifespan of hematopoietic stem cells.
Nature Med 12: 446–451.
38. Zhang Y, Herbert BS, Rajashekhar G, Ingram DA, Yoder MC, et al. (2009)
Premature senescence of highly proliferative endothelial progenitor cells is
induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein
kinase pathway. FASEB J 23: 1358–1365.
Doxorubicin-Induced Senescence in EPCs
PLoS ONE | www.plosone.org 11 December 2010 | Volume 5 | Issue 12 | e15583
39. Wada T, Stepniak E, Hui L, Leibbrandt A, Katada T, et al. (2008) Antagonistic
control of cell fates by JNK and p38-MAPK signaling. Cell Death Differ 15:
89–93.
40. Brookes S, Rowe J, Gutierrez Del Arroyo A, Bond J, Peters G (2004)
Contribution of p16(INK4a) to replicative senescence of human fibroblasts. Exp
Cell Res 298: 549–559.
41. Deng Q, Liao R, Wu BL, Sun P (2004) High intensity ras signaling induces
premature senescence by activating p38 pathway in primary human fibroblasts.
J Biol Chem 279: 1050–1059.
42. Timolati F, Ott D, Pentassuglia L, Giraud MN, Perriard JC, et al. (2006)
Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-
contraction coupling and reduces oxidative stress in adult rat cardiomyocytes.
J Mol Cell Cardiol 41: 845–854.
43. Kenneth R, Chien KR (2006) Herceptin and the Heart-A Molecular Modifier of
Cardiac Failure N Engl J Med 354: 789–790.
44. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of
chemotherapy plus a monoclonal antibody against HER2 for metastatic breast
cancer that overexpresses HER2. N Engl J Med 344: 783–792.
45. Hu Y, Davison F, Zhang Z, Xu Q (2003) Endothelial replacement and
angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating
progenitor cells. Circulation 108: 3122–3127.
46. Doyle B, Sorajja P, Hynes B, Kumar AH, Araoz PA, et al. (2008) Progenitor cell
therapy in a porcine acute myocardial infarction model induces cardiac
hypertrophy, mediated by paracrine secretion of cardiotrophic factors including
TGFb. Stem Cells Dev 17: 941–951.
47. Yang Z, von Ballmoos MW, Faessler D, Voelzmann J, Ortmann J, et al. (2010)
Paracrine factors secreted by endothelial progenitor cells prevent oxidative
stress-induced apoptosis of mature endothelial cells. Atherosclerosis 211:
103–109.
48. Murasawa S, Kawamoto A, Horii M, Nakamori S, Asahara T (2005) Niche-
dependent translineage commitment of endothelial progenitor cells, not cell
fusion in general, into myocardial lineage cells. Arterioscler Thromb Vasc Biol
25: 1388–1394.
Doxorubicin-Induced Senescence in EPCs
PLoS ONE | www.plosone.org 12 December 2010 | Volume 5 | Issue 12 | e15583
